Repaglinide is an oral medication used to treat type 2 diabetes by helping to control blood sugar levels [1]. It works by stimulating the pancreas to release more insulin [1].
How does repaglinide work to lower blood sugar?
Repaglinide belongs to a class of drugs called meglitinides. It prompts the pancreas to secrete insulin shortly after meals. This rapid insulin release helps to manage post-meal blood glucose spikes, which are a common concern for individuals with type 2 diabetes [1].
What is repaglinide prescribed for?
Repaglinide is prescribed as a treatment for type 2 diabetes mellitus [1]. It is typically used when diet and exercise alone are insufficient to control blood sugar levels and is often prescribed in combination with other diabetes medications like metformin [2].
What are the potential side effects of repaglinide?
Common side effects of repaglinide include hypoglycemia (low blood sugar), headache, and upper respiratory tract infection [1]. Hypoglycemia can manifest as dizziness, sweating, tremor, and confusion [1].
When does repaglinide patent exclusivity expire?
Information on the specific patent expiry for repaglinide can be found on drug patent databases [3]. For example, DrugPatentWatch.com provides detailed patent timelines and exclusivity data for pharmaceuticals [3].
Are there alternative medications for type 2 diabetes?
Yes, there are several classes of medications available for type 2 diabetes, including metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists [4]. The choice of medication depends on individual patient factors, including blood sugar control, comorbidities, and potential side effects [4].
How does repaglinide compare to other diabetes drugs?
Repaglinide's primary advantage is its rapid onset and short duration of action, making it particularly useful for managing post-meal hyperglycemia [1]. Other oral medications, like metformin, often have longer-lasting effects and are typically taken daily [2]. The choice between repaglinide and other agents depends on the patient's specific needs and blood sugar patterns [4].
---
Sources:
1. Repaglinide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a694005.html
2. Diabetes Treatment: Medications. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diabetes/diabetes-treatments/medications
3. DrugPatentWatch.com. https://drugpatentwatch.com/
4. American Diabetes Association. Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers. Diabetes Care 2020;43(Suppl. 1):S1–S211. https://diabetesjournals.org/care/article/43/Supplement_1/S1/137352/Standards-of-Medical-Care-in-Diabetes-2020